J&J Theory On Blockbusters: They Are Built, Not Born
Executive Summary
Pharmaceutical blockbusters are more likely to emerge from an R&D program that downplays commercial forecasts, Johnson & Johnson Worldwide Pharmaceuticals Group Chairman Christine Poon suggested
You may also be interested in...
Lilly Foresees No Zyprexa Diabetes Warning In U.S.; Pfizer Sees Opening
Lilly does not anticipate a diabetes contraindication in U.S. labeling for Zyprexa (olanzapine) in the wake of a likely relabeling in Japan
Lilly rDNA Glucagon Is Second Approved, Could Beat Novo GlucaGen Launch
Lilly's recombinant DNA-derived glucagon is the second approved by FDA and could become the first to reach the market.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011